Key regions: Japan, Italy, China, South Korea, Brazil
The COVID-19 pandemic has had a significant impact on the global healthcare industry, with the development and distribution of vaccines at the forefront of the response. Bosnia and Herzegovina, like many other countries, has been working to secure an adequate supply of vaccines to immunize its population.
Customer preferences: The preference for COVID-19 vaccines in Bosnia and Herzegovina is similar to that of other countries, with a focus on the safety and efficacy of the vaccine. However, due to the limited supply of vaccines, priority has been given to high-risk groups, such as healthcare workers and the elderly.
Trends in the market: The COVID-19 vaccine market in Bosnia and Herzegovina is still in its early stages, with the majority of vaccines being imported from other countries. The government has been working to secure additional supplies of vaccines, including through the COVAX initiative. As the supply of vaccines increases, more of the population will become eligible for vaccination, and the market will continue to grow.
Local special circumstances: Bosnia and Herzegovina is a lower-middle-income country, which has had an impact on the availability of vaccines. The government has been working to secure additional funding to purchase vaccines, but the limited resources have made it difficult to secure a large supply. Additionally, the country has a complex political structure, which has led to challenges in coordinating the response to the pandemic.
Underlying macroeconomic factors: The COVID-19 pandemic has had a significant impact on the Bosnian economy, with a contraction of GDP and an increase in unemployment. This has made it difficult for the government to secure the funding needed to purchase vaccines. Additionally, the pandemic has highlighted the need for investment in the healthcare system, which has been underfunded for many years. As the country works to recover from the pandemic, there will likely be increased investment in the healthcare system, which could lead to long-term growth in the vaccine market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
